• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Adaptive Biotechnologies (ADPT) Still Below Fair Value On Mixed Q3 Results?

    Simply Wall St·11/09/2026 09:28:13
    Listen to the news

    Adaptive Biotechnologies (ADPT) has investors parsing fresh third quarter 2026 earnings, with lower sales and profit than a year earlier but higher year to date revenue and a deeper cumulative loss.

    Recent trading action suggests investors are leaning into the story again. Adaptive Biotechnologies shows a 1 day share price return of 4.29%, a 7 day gain of 11.65% and a year to date share price return of 75.86%. The 1 year total shareholder return of 90.21% and very large 3 year total shareholder return of roughly 7x point to strong long term momentum, although the 5 year total shareholder return is still down 14.12%.

    Spot fresh momentum in Adaptive Biotechnologies and then widen your watchlist with hand picked peers showing similar strength across 35 healthcare AI stocks.

    The sharp rise in Adaptive Biotechnologies now sits against softer recent earnings and a deeper year to date loss. Is this move really tracking business progress, or just a sentiment swing that the valuation needs to test?

    Most Popular Narrative: 7% Undervalued

    Adaptive Biotechnologies closed at $27.98, while the analyst consensus Narrative on Simply Wall St points to a fair value near $30.21. This implies a modest discount that is based on the strength of the MRD business and future cash flows under an 8.08% discount rate.

    Marked improvement in profitability in Adaptive Biotechnologies’ MRD segment, including sequencing gross margin in the low 70% range and positive segment EBITDA in early 2026 together with guidance for company-wide positive adjusted EBITDA and free cash flow by the end of 2026, indicates rising operating leverage that can support future net margin expansion.

    See why 8 investors see Adaptive Biotechnologies as 7% undervalued.

    Result: Fair Value of $30.21 (UNDERVALUED)

    Still, this narrative can crack if clonoSEQ pricing comes under pressure from Medicare limits or if the refocused Immune Medicine unit fails to land new pharma deals.

    Find out about the key risks to this Adaptive Biotechnologies narrative.

    Next Steps

    Feeling torn between the bullish tone and the earnings drag around Adaptive Biotechnologies? Move quickly, review the numbers yourself, and weigh up the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Adaptive Biotechnologies?

    If Adaptive Biotechnologies has your attention, do not stop here. Use the Simply Wall St Screener to hunt for fresh opportunities before others move first.